J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure
Executive Summary
Johnson & Johnson is expected to keep pursuing Actelion despite news the target's pulmonary arterial hypertension drug macitentan missed a primary endpoint in a Phase III study of patients with PAH due to Eisenmenger Syndrome.
You may also be interested in...
Can Actelion Founder Clozel Recreate Another Top Biotech Post-J&J Sale?
Actelion's M&A deal with J&J vindicates the strategy of cardiologist Jean-Paul Clozel, who co-founded the Swiss firm with his wife Martine and friends in 1997, and positions him for another shot at biotech success.
Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing
CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.
Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making
PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.